The real-world safety profile of pemetrexed and platinum with or without pembrolizumab: insights from a comparative analysis of FAERS database
In the real world, combination therapy increases the risk of certain AEs, particularly in specific patient subgroups. These findings emphasize the importance of personalized treatment strategies and AE monitoring, particularly during the first three months of therapy.
Authors
- Yanwen Zhou (ORCID: https://orcid.org/0000-0003-3636-0123)
- Zhifei Huang
- Shun Li (ORCID: https://orcid.org/0000-0001-6060-7259)
- Hao Jiang (ORCID: https://orcid.org/0000-0001-7200-5087)
- Xiaoyu Zhong
Institutions
- Bengbu Medical College (CN)
- First Affiliated Hospital of Bengbu Medical College (CN)
Publication Details
- Journal
- BMC Cancer
- Published
- 2025-04-24
- DOI
- https://doi.org/10.1186/s12885-025-14171-3
- Citations
- 6
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 6.27